HilleVax Inc (HLVX) 뉴스

HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million...

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for...

Form 4 - Statement of changes in beneficial ownership of securities

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical...

Form 8-K - Current report

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage...

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 144 - Report of proposed sale of securities